Molecular cytogenetics market seen reaching $8.52 billion by 2035

Market Research Future projects the global molecular cytogenetics market will grow from $3.72 billion in 2026 to $8.52 billion by 2035, driven by faster regulatory clearances, broader reimbursement and a shift toward AI-enabled lab workflows. The outlook points to stronger demand in oncology, prenatal testing and cloud-based diagnostic services across North America and Asia-Pacific.

Why it matters: - Molecular cytogenetics is moving deeper into routine cancer care, prenatal screening and genetic disorder testing. - The market’s growth reflects demand for faster, more automated chromosomal testing that can reduce labor needs and speed diagnosis. - Broader reimbursement and regulatory support are helping pull these tests into mainstream laboratory procurement. - Market Research Future projects the global market will rise from $3.72 billion in 2026 to $8.52 billion by 2035, a 10.15% compound annual growth rate.

What happened: - Market Research Future released a forecast for the molecular cytogenetics market covering 2026-2035. - The report says the market base was estimated at $3.40 billion in 2025. - The forecast cites three main growth drivers: FDA accelerated clearance pathways for next-generation FISH panels, expanded Medicare reimbursement codes and a shift from legacy karyotyping toward automated array CGH platforms and AI-driven image interpretation software. - The report also says the NIH allocated more than $420 million to genomic infrastructure modernization between 2023 and 2025. - The report says the FDA finalized its Laboratory Developed Tests framework in April 2024. - The WHO projects AI-assisted cytogenetic testing could reduce diagnostic errors by 35%-40% globally by 2030. - The source includes a free sample request, a customization request and the full report.

The details: - Kits and reagents held about 58% of 2025 revenue, making them the largest product segment. - Software and services are projected to grow the fastest at 13.10% CAGR from 2026 to 2035. - Instruments were valued at $0.68 billion in 2025. - FISH held about 62% of 2025 revenue and remained the dominant technique. - Array comparative genomic hybridization is expected to grow fastest at 16.90% CAGR through 2035. - Other techniques, including spectral karyotyping and digital PCR, accounted for $0.22 billion in 2025. - Cancer testing represented about 63% of 2025 revenue. - Personalized medicine is projected to grow the fastest at 18.95% CAGR. - Genetic disorders accounted for $0.52 billion in 2025. - Clinical and research laboratories held about 49% of the end-user share in 2025. - Hospitals and diagnostic centers generated $0.88 billion in 2025. - Pharma, biotech and CROs are projected to grow fastest at 14.90% CAGR. - Abbott Laboratories, Agilent Technologies, Illumina and Thermo Fisher Scientific are listed among key companies in the market. - Abbott received FDA approval in April 2022 for its Vysis CLL FISH Probe Kit as a companion diagnostic for chronic lymphocytic leukemia. - Agilent is highlighted for Array CGH microarrays and SureFISH probes. - Illumina is cited for sequencing-adjacent cytogenomic solutions and clinical-grade arrays. - Thermo Fisher is cited for FISH reagents and Applied Biosystems instruments.

Between the lines: - Reimbursement and clearance changes matter because molecular cytogenetics depends on repeat testing, not one-off purchases. - AI and cloud reporting are lowering the staffing and capital barriers that have limited adoption in smaller labs and developing markets. - The report’s regional breakdown suggests the next wave of volume growth will come from Asia-Pacific, where China and India are expanding precision-medicine infrastructure. - North America remains the largest market because payer coverage and companion diagnostics have already built a clinical demand base. - Europe’s growth is being shaped by regulatory harmonization, while the Middle East and Africa still face workforce and infrastructure constraints. - The report also points to market consolidation, with integrated vendors gaining share as buyers favor bundled instruments, reagents and software.

What’s next: - The report expects AI-augmented chromosomal analysis to become a core workflow by 2030. - It says machine learning systems are approaching expert-level accuracy in chromosomal abnormality detection. - The report forecasts top-five suppliers could control more than 55% of global revenue by 2032. - Lower per-device costs are expected to broaden adoption beyond reference labs into community hospitals and regional clinics. - Market Research Future points to continued growth in companion diagnostics, oncology testing and cloud-based cytogenetic services through 2035.

The bottom line: - Molecular cytogenetics is shifting from a specialized lab niche to a more automated, reimbursement-backed clinical testing market, with software and AI emerging as the biggest growth catalysts.